Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 41,200 shares, a growth of 396.4% from the December 31st total of 8,300 shares. Based on an average trading volume of 27,200 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.2% of the company’s shares are sold short.
Dominari Price Performance
Shares of DOMH remained flat at $2.00 on Tuesday. 274,577 shares of the company were exchanged, compared to its average volume of 129,075. The stock’s 50 day simple moving average is $1.40 and its 200 day simple moving average is $1.63. Dominari has a twelve month low of $0.83 and a twelve month high of $3.20. The stock has a market cap of $12.68 million, a PE ratio of -0.52 and a beta of 1.03.
Dominari (NASDAQ:DOMH – Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.45) earnings per share (EPS) for the quarter. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%. The company had revenue of $4.04 million during the quarter.
About Dominari
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
See Also
- Five stocks we like better than Dominari
- What Are Treasury Bonds?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Breakout Stocks: What They Are and How to Identify Them
- What Does the Future Hold for Eli Lilly?
- Investing in Commodities: What Are They? How to Invest in Them
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.